Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has refocused scientific interest on gaining insight into the pathophysiology of systemic viral diseases. Complement activation has been characterized as a driver of endothelial injury and microvascular thrombosis in a...
Gespeichert in:
| Veröffentlicht in: | Clinical kidney journal 2023-12, Vol.16 (12), p.2750-2753 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2753 |
|---|---|
| container_issue | 12 |
| container_start_page | 2750 |
| container_title | Clinical kidney journal |
| container_volume | 16 |
| creator | Aberger, Simon Kozakowski, Nicolas Proházka, Zoltán Pleininger, Thomas Salmhofer, Hermann |
| description | The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has refocused scientific interest on gaining insight into the pathophysiology of systemic viral diseases. Complement activation has been characterized as a driver of endothelial injury and microvascular thrombosis in acute respiratory distress syndrome as well as hantavirus hemorrhagic fever with renal syndrome. On this occasion, we wish to report a case of severe hantavirus disease with coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy with rapid response of inflammatory markers, hematologic parameters and proteinuria to eculizumab. These findings support a disease model of virus-associated endothelial injury involving alternative pathway complement activation. Future studies are needed to explore whether end organ damage can be mitigated by complement inhibition in life-threatening viral disease. |
| doi_str_mv | 10.1093/ckj/sfad222 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A776923320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A776923320</galeid><oup_id>10.1093/ckj/sfad222</oup_id><sourcerecordid>A776923320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-d16c11b2b01cb4c01180a3d1fdb171230fcf04aeaad272573374eacd3d72cae73</originalsourceid><addsrcrecordid>eNp9kdtKAzEQhhdRsNRe-QIBwRvZNofdbntZ6hEKglVvl9lJ0qbtJiXZCvUNfGvTA4IgZi4yzHzzw8yfJJeMdhkdih4uF72gQXLOT5IWp9kgHeRMnP7kND9POiEsaHyxQ7O8lXzdusrDB5A52AY-jN8EAlYSdMaikcbOyHT0Mk3H7j3lxFitsDHOktrUBpe7djP3rq5cYzAW0TuwM-PW0My3eyGvwtrZvVDjCJAQs5Ui0gVFnCYKNyvzuamhukjONKyC6hz_dvJ2f_c6fkwnzw9P49EkRcH7TSpZHxmreEUZVhlSxgYUhGRaVqxgXFCNmmagIB6i4HkhRJEpQClkwRFUIdrJ1UF3BitVxo1c4wFrE7AcFUV_yIXgNFLdP6gYUsUtnVXaxPqvgZvDQDxBCF7pcu1NDX5bMlru_CmjP-XRn0hfH2i3Wf8LfgPiv5Ln</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Aberger, Simon ; Kozakowski, Nicolas ; Proházka, Zoltán ; Pleininger, Thomas ; Salmhofer, Hermann</creator><creatorcontrib>Aberger, Simon ; Kozakowski, Nicolas ; Proházka, Zoltán ; Pleininger, Thomas ; Salmhofer, Hermann</creatorcontrib><description>The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has refocused scientific interest on gaining insight into the pathophysiology of systemic viral diseases. Complement activation has been characterized as a driver of endothelial injury and microvascular thrombosis in acute respiratory distress syndrome as well as hantavirus hemorrhagic fever with renal syndrome. On this occasion, we wish to report a case of severe hantavirus disease with coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy with rapid response of inflammatory markers, hematologic parameters and proteinuria to eculizumab. These findings support a disease model of virus-associated endothelial injury involving alternative pathway complement activation. Future studies are needed to explore whether end organ damage can be mitigated by complement inhibition in life-threatening viral disease.</description><identifier>ISSN: 2048-8505</identifier><identifier>EISSN: 2048-8513</identifier><identifier>DOI: 10.1093/ckj/sfad222</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Acute respiratory distress syndrome ; Analysis ; Blood clot ; Coronaviruses ; Endothelium ; Epidemics ; Health aspects ; Hemorrhagic fever ; Medical research ; Medicine, Experimental ; Severe acute respiratory syndrome ; Thrombosis</subject><ispartof>Clinical kidney journal, 2023-12, Vol.16 (12), p.2750-2753</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. 2023</rights><rights>COPYRIGHT 2023 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-d16c11b2b01cb4c01180a3d1fdb171230fcf04aeaad272573374eacd3d72cae73</cites><orcidid>0000-0003-1761-7982 ; 0000-0001-9180-620X ; 0000-0002-5721-2595 ; 0000-0003-2398-2978</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,1604,27924,27925</link.rule.ids></links><search><creatorcontrib>Aberger, Simon</creatorcontrib><creatorcontrib>Kozakowski, Nicolas</creatorcontrib><creatorcontrib>Proházka, Zoltán</creatorcontrib><creatorcontrib>Pleininger, Thomas</creatorcontrib><creatorcontrib>Salmhofer, Hermann</creatorcontrib><title>Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab</title><title>Clinical kidney journal</title><description>The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has refocused scientific interest on gaining insight into the pathophysiology of systemic viral diseases. Complement activation has been characterized as a driver of endothelial injury and microvascular thrombosis in acute respiratory distress syndrome as well as hantavirus hemorrhagic fever with renal syndrome. On this occasion, we wish to report a case of severe hantavirus disease with coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy with rapid response of inflammatory markers, hematologic parameters and proteinuria to eculizumab. These findings support a disease model of virus-associated endothelial injury involving alternative pathway complement activation. Future studies are needed to explore whether end organ damage can be mitigated by complement inhibition in life-threatening viral disease.</description><subject>Acute respiratory distress syndrome</subject><subject>Analysis</subject><subject>Blood clot</subject><subject>Coronaviruses</subject><subject>Endothelium</subject><subject>Epidemics</subject><subject>Health aspects</subject><subject>Hemorrhagic fever</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Severe acute respiratory syndrome</subject><subject>Thrombosis</subject><issn>2048-8505</issn><issn>2048-8513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kdtKAzEQhhdRsNRe-QIBwRvZNofdbntZ6hEKglVvl9lJ0qbtJiXZCvUNfGvTA4IgZi4yzHzzw8yfJJeMdhkdih4uF72gQXLOT5IWp9kgHeRMnP7kND9POiEsaHyxQ7O8lXzdusrDB5A52AY-jN8EAlYSdMaikcbOyHT0Mk3H7j3lxFitsDHOktrUBpe7djP3rq5cYzAW0TuwM-PW0My3eyGvwtrZvVDjCJAQs5Ui0gVFnCYKNyvzuamhukjONKyC6hz_dvJ2f_c6fkwnzw9P49EkRcH7TSpZHxmreEUZVhlSxgYUhGRaVqxgXFCNmmagIB6i4HkhRJEpQClkwRFUIdrJ1UF3BitVxo1c4wFrE7AcFUV_yIXgNFLdP6gYUsUtnVXaxPqvgZvDQDxBCF7pcu1NDX5bMlru_CmjP-XRn0hfH2i3Wf8LfgPiv5Ln</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Aberger, Simon</creator><creator>Kozakowski, Nicolas</creator><creator>Proházka, Zoltán</creator><creator>Pleininger, Thomas</creator><creator>Salmhofer, Hermann</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-1761-7982</orcidid><orcidid>https://orcid.org/0000-0001-9180-620X</orcidid><orcidid>https://orcid.org/0000-0002-5721-2595</orcidid><orcidid>https://orcid.org/0000-0003-2398-2978</orcidid></search><sort><creationdate>20231201</creationdate><title>Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab</title><author>Aberger, Simon ; Kozakowski, Nicolas ; Proházka, Zoltán ; Pleininger, Thomas ; Salmhofer, Hermann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-d16c11b2b01cb4c01180a3d1fdb171230fcf04aeaad272573374eacd3d72cae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute respiratory distress syndrome</topic><topic>Analysis</topic><topic>Blood clot</topic><topic>Coronaviruses</topic><topic>Endothelium</topic><topic>Epidemics</topic><topic>Health aspects</topic><topic>Hemorrhagic fever</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Severe acute respiratory syndrome</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aberger, Simon</creatorcontrib><creatorcontrib>Kozakowski, Nicolas</creatorcontrib><creatorcontrib>Proházka, Zoltán</creatorcontrib><creatorcontrib>Pleininger, Thomas</creatorcontrib><creatorcontrib>Salmhofer, Hermann</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Clinical kidney journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aberger, Simon</au><au>Kozakowski, Nicolas</au><au>Proházka, Zoltán</au><au>Pleininger, Thomas</au><au>Salmhofer, Hermann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab</atitle><jtitle>Clinical kidney journal</jtitle><date>2023-12-01</date><risdate>2023</risdate><volume>16</volume><issue>12</issue><spage>2750</spage><epage>2753</epage><pages>2750-2753</pages><issn>2048-8505</issn><eissn>2048-8513</eissn><abstract>The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has refocused scientific interest on gaining insight into the pathophysiology of systemic viral diseases. Complement activation has been characterized as a driver of endothelial injury and microvascular thrombosis in acute respiratory distress syndrome as well as hantavirus hemorrhagic fever with renal syndrome. On this occasion, we wish to report a case of severe hantavirus disease with coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy with rapid response of inflammatory markers, hematologic parameters and proteinuria to eculizumab. These findings support a disease model of virus-associated endothelial injury involving alternative pathway complement activation. Future studies are needed to explore whether end organ damage can be mitigated by complement inhibition in life-threatening viral disease.</abstract><pub>Oxford University Press</pub><doi>10.1093/ckj/sfad222</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1761-7982</orcidid><orcidid>https://orcid.org/0000-0001-9180-620X</orcidid><orcidid>https://orcid.org/0000-0002-5721-2595</orcidid><orcidid>https://orcid.org/0000-0003-2398-2978</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2048-8505 |
| ispartof | Clinical kidney journal, 2023-12, Vol.16 (12), p.2750-2753 |
| issn | 2048-8505 2048-8513 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A776923320 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Acute respiratory distress syndrome Analysis Blood clot Coronaviruses Endothelium Epidemics Health aspects Hemorrhagic fever Medical research Medicine, Experimental Severe acute respiratory syndrome Thrombosis |
| title | Dobrava hantavirus and coinciding SARS-CoV-2 infection mimicking thrombotic microangiopathy and responding to a single dose of eculizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A04%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dobrava%20hantavirus%20and%20coinciding%20SARS-CoV-2%20infection%20mimicking%20thrombotic%20microangiopathy%20and%20responding%20to%20a%20single%20dose%20of%20eculizumab&rft.jtitle=Clinical%20kidney%20journal&rft.au=Aberger,%20Simon&rft.date=2023-12-01&rft.volume=16&rft.issue=12&rft.spage=2750&rft.epage=2753&rft.pages=2750-2753&rft.issn=2048-8505&rft.eissn=2048-8513&rft_id=info:doi/10.1093/ckj/sfad222&rft_dat=%3Cgale_cross%3EA776923320%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A776923320&rft_oup_id=10.1093/ckj/sfad222&rfr_iscdi=true |